



Università Cattolica del Sacro Cuore
Facoltà di Medicina e Chirurgia

Complesso Integrato Columbus



*Clinica di Reumatologia
Scuola di Specializzazione in Reumatologia
SC Dottorato in Proteomica Clinica
Direttore: Prof. G.F. Ferraccioli*

Roma, 31/12/2015

Sede del Progetto:
*Università Cattolica del Sacro Cuore –
Istituto di Reumatologia con responsabile Prof GF. Ferraccioli
in collaborazione con Istituto di Microbiologia Professor Sanguinetti.*

Coordinatore del progetto: Dottoressa Silvia Laura Bosello

Title: Role of microbiota in the pathogenesis of scleroderma: correlations with nutritional status and with gastroenteric involvement.

Report

Gastrointestinal involvement (GI) is frequent in systemic sclerosis (SSc) and it is the presenting feature of the disease in 10% of patients [1,2]. Whilst severe gastrointestinal involvement affects only 8% of SSc patients, the associated mortality is very high and only 15% of these patients is alive 9 years after diagnosis. In particular, malabsorption is a very poor prognostic factor with a 50% mortality rate at 8.5 years. [3,4]. Gastrointestinal manifestations of SSc impact severely not only on prognosis but also on quality of life and are a cause of depression in SSc patients [3]. Unfortunately, gastrointestinal involvement is often noticed only when severe complications have already occurred and treatment options are limited. The pathophysiology of GI involvement in SSc is not clear and only few studies have investigated the pathology of the intestinal system. A four steps pathogenetic process, similar to that occurring in the skin, has been proposed. The first step is an early vascular lesion, which manifests as mild changes in intestinal permeability, transport and absorption, and is followed by neural dysfunction and then smooth muscle atrophy, while the last steps is muscle fibrosis [6].

The most frequent GI organ involved is the oesophagus, followed by the anorectum and the small bowel. The altered peristaltic activity with multiple secondary problems lead to oesophageal reflux, early satiety, nausea, vomiting, pseudo-obstruction, small intestine bacterial overgrowth, malabsorption and, ultimately, malnutrition.

Assessment of nutritional status is generally difficult and no tools are yet validated to measure gastrointestinal involvement in SSc [7]. It has been proposed the use of gastrointestinal questionnaire used by the Canadian Scleroderma Research Group (structured 14 questions on GI symptoms), the UCLA scleroderma clinical trial consortium GIT 2.0 questionnaire (34 items and 7 multiter scales focused on reflux, distension/bloating, diarrhea, fecal spoilage, constipation, emotional well being and social functioning), and the MUST (malnutrition universal screening tool) that combines BMI and weight loss measures [8]. Using this latest tool, a Canadian study demonstrates an important risk of malnutrition in SSc, with more than 28% of patients at medium- or high-risk [9].

Commento [M1]: Controllare

The pathogenesis of systemic sclerosis is not well understood but it is thought that environmental factors determine the onset of the disease in genetically predisposed subjects and the major human organs that are exposed to environment are the skin and the gut. The human gut is an ecosystem consisting of a great number of commensal bacteria living in symbiosis with the host, number which far exceed the number of cells in one's human body. Several data confirm that gut microbiota is engaged in a dynamic interaction with the intestinal innate and adaptive immune system, affecting different aspects of its development and function [10]. The intestinal microflora has a protective, metabolic, trophic and immunological function and is able to establish a "cross-talk" with the immune component of mucosal immunity, comprising cellular (B cells with sIgA, mucosal T cells, epithelial cells) and soluble elements (i.e. interleukines) [11]. A shift in composition of the gut microbiota may cause either a pathological or beneficial outcome mediated by the regulation of particular T cell subtypes influenced by the gut microbiota.

The gut commensal bacteria may dictate a pro- or anti-inflammatory environment that can have a substantial impact on the adaptive immune response away from the gut, suggesting that gut micro-environment, sex and genetic factors may be able to predict susceptibility to develop autoimmunity [10]. With the recent advances in technology, it is now possible to sequence the commensal bacteria present in the human gut and experimental data support the hypothesis that alteration of the gut microbiota is supposed to be involved in the development of different disease, such as atopic illness, inflammatory bowel disease (IBD) [13, 14], rheumatoid arthritis (RA) [15,16] and systemic lupus erythematosus [17].

Accumulating evidence suggests that IBD is the consequence of an inappropriate inflammatory response to intestinal bugs in a genetically susceptible host [13,14]. It is known that the microbiota of these patients is different from the one of healthy controls: comparison between 161 faecal samples from patients affected by Crohn's disease versus 121 healthy samples showed depletion of the class Clostridia and the genus Bifidobacterium and an increase of the genus Bacteroides; in addition, the composition of the microbiota was different between the two groups depending on the activity status of the intestinal illness. For this reason, fecal microbiota is may be a possible marker of disease activity [18]. The analysis of fecal microbiota of RA patients conducted by PCR of 16S RNA sequencing of microbes present in the stool showed a different pattern of bacteria respect with patients with fibromyalgia [15]. The studies on microbiota in human and in autoimmune disease mouse models suggest that the intestine may be a critical organ in triggering disease through an altered immune homeostasis and that a leaky gut with proinflammatory conditions may be an event that begins before the onset of clinical phenotype of a disease.

The microbiota not only maintains a balanced mucosal immune system but also aids in digesting certain food and harvesting energy and increasing evidences indicate that the plays a significant role in maintaining a satisfactory nutritional state as well as in the development of obesity, obesity-associated inflammation and insulin resistance. Differences in composition and in genetic and metabolic activities of the gut microbiota seems to be able to stratify patients with different

nutritional status, suggesting that gut “dysbiosis” contributes to the development of obesity and malnutrition and their complications. In obese individuals and in animal models, there is a deregulation of gut permeability and bacterial translocation to the host, that probably promotes the systemic inflammation, that is the hallmark of the obese state [19]. Finally, some evidences support the use of probiotics and prebiotics, with beneficial effect for the treatment of the diseases caused by the dysregulation of the immune system [12, 20-21], opening possible intervention in autoimmune diseases characterized by modification of microbiota.

To investigate the characteristics of gut microbiota in systemic sclerosis patients we enrolled in 65 patients with Systemic sclerosis. The mean age is 56.0 ± 15.0 years and the mean disease duration is 13.0 ± 10.0 years, in particular 33% of the patients has an early disease. Forty-two percent presented a positivity for antitopoisomerase antibodies, and 35% have a positivity of anticentromere antibodies and 23% was only ANA positive. For all enrolled patients we collected serum sample, stool sample and we investigated the metabolic characteristics. The mean BMI is 24.0 ± 5.0 kg/cm², 64.6% of the patients were normal-weight, 18.5% were overweight, 9% were obese, while only 16.9% were underweight.

In our enrolled cohort the mean levels of cholesterol is 170 ± 37.0 mg/dl, the mean HDL levels is 52.0 ± 16.0 mg/dl, the mean levels of triglycerides is 92.0 ± 41.0 mg/dl, the mean albumin levels is 4.0 ± 0.4 g/dl, the mean haemoglobin levels is 12.0 g/dl ± 1.4 . The mean levels of vitamin D is 26.0 ± 14.0 ng/ml, the mean levels of folates is 9.0 ± 5.0 ng/ml and the mean levels of vitamin B12 is 460.0 ± 322.0 pg/ml.

All patients answered the Canadian Scleroderma Research Group and the GIT 2.0 questionnaire (34 items and 7 multiter scales focused on reflux, distension/bloating, diarrhea, fecal spoilage, constipation, emotional well being and social functioning). The mean UCLA GIT2.0 score is 0.42 ± 0.33 and the mean CSR score is 2.3 ± 1.7 .

Fifty age, gender and weight matched healthy controls were also enrolled and the stool specimens were available.

All stool specimens were collected to characterize the composition of the intestinal microflora in the different subsets of SSc and in patients with different nutritional status to study if specific microbial species may be responsible of dysbiosis in SSc patients.

The analysis of fecal microbiota of SSc patients conducted by PCR of 16S RNA sequencing of microbes present in the stool showed a different pattern of bacteria respect with healthy control patients. Our preliminary data similar to chronic inflammatory states, such as inflammatory bowel disease (IBD), suggest that SSc patients had decreased commensal genera, such as *Bacteroides*, and increased pathogenic genera, such as *Enterobacteriales* compared with healthy controls. The relationship between the microbial consortium and GIT symptoms was also explored and will be presented after a complete analysis that is in progress at now.

This study suggests a possible distinct microbial signature in the stool of SSc patients compared with healthy controls, but a complete analysis of different species will be ready in the next few months for a more exhaustive description of differences and similarities in scleroderma patients respect with the controls. A unique ecological change peculiar of scleroderma may perpetuate immunological aberrations and contribute to clinical manifestations of SSc.

Bibliography

1. Tian XP, Zhang X. Gastrointestinal complications of systemic sclerosis. *World J Gastroenterol* 2013 Nov 7;19(41):7062-8.
2. Lepri G, Guiducci S, Bellando-Randone S, et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. *Ann Rheum Dis*. 2014 Jan 28.
3. Steen VD, Medsger Jr TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. *Arthritis Rheum* 2000;43:2437-44
4. Gyger G, Baron M. Gastrointestinal manifestation in scleroderma: recent progress in evaluation, pathogenesis and management. *Curr Rheumatol Rep* 2012;14:22-29.
5. Franck-Larsson K, Graf W, Ronnblom A. Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis: a population-based study. *Eur J Gastroenterol Hepatol*. 2009; 21:176- 82.
6. Sjogren RW. Gastrointestinal motility disorders in scleroderma. *Arthritis Rheum* 1994;37: 1265-82
7. Baron M, Bernier P, DeLegge MH, Falovitch G, Friedman G, Gornitsky M, et al. Screening and management for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendation of a North American expert panel. *Clin Exp Rheum* 2010; 28:S42-46.
8. Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclerosis. *Current opinion Rheumatol* 2013;25:700-706.
9. Baron M, Hudson M, Steele R. Malnutrition is common in systemic sclerosis: results from the Canadian Scleroderma Research Group Database. *J Rheumatol*. 2009;36:2737-43.

10. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes*. 2012;31:4-14.
11. Kato LM, Kawamoto S, Maruya M, Fagarasan S. The role of the adaptive immune system in regulation of gut microbiota. *Immunol reviews* 2014;260:67-75.
12. Purchiatoni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Uaniro G, et al. The role of intestinal microbiota and the immune system. *Eur rev Med pharmacol Sci* 2013;17:323-33.
13. Huttenhower C, Kostic AD, Xavier R. Inflammatory bowel disease as a model for translating the microbiome. *Immunity* 2014;40: 843-854.
14. Swidsinki A, Ladhoff A, Perthaler A, Swidsinki S, Loening-Baucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. *Gastroenterology* 2002;122:44-54.
15. Vaahtouvo J, Munukka E, Korkeamaki M, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. *J Rheumatol* 2008;35:1500-1505
16. Taneja V. Arthritis susceptibility and the gut microbiome. *FEBS letter* 2014, doi.10.1016.
17. Vieira Sm , Pagovich OE, Kriegel MA. Diet, microbiota and autoimmune diseases. *Lupus* 2014;23: 518-526
18. Fukuda k, Fujita Y. Determination of the discriminant score of intestinal microbiota as a biomarker of disease activity in patients with ulcerative colitis. *BMC Gastroenterology* 2014; 14:49.
19. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. *Mol Aspects Med*. 2013 Feb;34(1):39-58.
20. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. *Gastroenterology*. 2004;126:1620-33.
21. Scalfaferrri F, Lopetuso LR, Petito V, Cufino V, Bilotta M, Arena V, et al. Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota

composition: Emerging role for 'gut barrier protectors' in IBD? United European
Gastroenterol J. 2014;2:113-22.

Sherman/Boxell